Access to biologic drugs is uneven, even in nations with relatively robust healthcare resources. In lower-resource areas, such as Eastern Europe, access to biologic therapy for diseases like inflammatory bowel disease (IBD) may be very limited.
Access to biologic drugs is uneven, even in nations with relatively robust healthcare resources. In lower-resource areas, such as Eastern Europe, access to biologic therapy for diseases like inflammatory bowel disease (IBD) may be very limited.
However, with the introduction of biosimilars, more patients may be able to gain access to effective treatment; a multicenter, observation cohort study demonstrated that, among patients with ulcerative colitis (UC) and Crohn disease (CD), biosimilar infliximab CT-P13 (Inflectra, Remsima) was safe and effective, and it provided a cost-effective alternative to the reference (Remicaid).
The study was conducted at sites in Romania, the Czech Republic, and Bulgaria, and the 85 patients enrolled were adults with moderate to severe CD (n = 38) or UC (n = 47). The patients, 80% of whom were naïve to infliximab, received treatment with CT-P13 for up to 30 weeks.
At week 30, the response rate was 65.8% (95% CI, 49.8%-78.9%) among patients with CD and 55.3% (95% CI, 41.2%-68.6%) in patients with UC. Remission rates were 47.4% (95% CI, 32.5%-62.7%) and 48.9% (95% CI, 35.3%-62.8%) in the 2 groups, respectively.
In the combined patient population, quality of life improved significantly over the observation period; the mean Short Inflammatory Bowel Disease Questionnaire score increased from 40.0 (±11.3) at baseline to 56.2 (±9.3) at the end of treatment (P < .0001).
Of 31 total adverse events (AEs) observed, 2 were considered to be related to infliximab. Both were infusion-related reactions, 1 of which led to discontinuation.
The authors note that a budget impact analysis in European nations that included Romania and the Czech Republic showed that using biosimilar infliximab in place of its reference in patients with CD could allow 700 to 1500 additional patients to be treated. Another model, conducted in the Netherlands, found that cost savings resulting from biosimilar use could reach 30%, and in 2015, biosimilar infliximab was projected to produce annual direct drug cost savings in several European countries of 10% to 30%.
“Together with other studies reporting on the effectiveness and tolerability of biosimilar infliximab in patients with chronic inflammatory conditions including IBD, the weight of evidence suggests that biosimilar infliximab is an effective and cost-effective replacement for originator infliximab,” conclude the authors.
Reference
Gheorghe C, Svoboda P, Mateescu B. Effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting in patients with Crohn’s disease or ulcerative colitis. J Drug Assess. 2019;8(1):129-134. doi: 10.1080/21556660.2019.1626735.
Spanish Real-World Study: Adalimumab Biosimilar MSB11022 Safe, Effective in IBD
May 18th 2024A real-world study in Spain on inflammatory bowel disease (IBD) patients found no meaningful changes in clinical or biochemical markers or differences in effectiveness between the adalimumab originator and the biosimilar MSB11022 (Idacio; Fresenius Kabi) in adalimumab-naïve patients.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.